

RESEARCH

Open Access



Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study

Shinichiro Yamada*, Yuji Morine, Tetsuya Ikemoto, Yu Saito, Hiroki Teraoku, Yuhei Waki, Chiharu Nakasu and Mitsuo Shimada

Abstract

Background We investigated the usefulness of apparent diffusion coefficients (ADC) from diffusion-weighted images (DWI) obtained using magnetic resonance imaging (MRI) for prognosis of early hepatocellular carcinoma (HCC): Barcelona Clinic Liver Cancer (BCLC) stage 0 and A.

Methods We enrolled 102 patients who had undergone surgical resection for early HCC: BCLC stage 0 and A, and calculated their minimum ADC using DWI-MRI. We divided patients into ADC^{High} (n = 72) and ADC^{Low} (n = 30) groups, and compared clinicopathological factors between the two groups.

Results The ADC^{Low} group showed higher protein induced by vitamin K absence-II (PIVKA-II) levels (p = 0.02) compared with the ADC^{High} group. In overall survival, the ADC^{Low} group showed significantly worse prognosis than the ADC^{High} group (p < 0.01). Univariate analysis identified multiple tumors, infiltrative growth, high PIVKA-II, and low ADC value as prognostic factors. Multivariate analysis identified infiltrative growth and low ADC value as an independent prognostic factor.

Conclusion ADC values can be used to estimate the prognosis of early HCC.

Keywords Magnetic resonance imaging, Apparent diffusion coefficient, Hepatocellular carcinoma, Prognostic prediction

Background

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide [1]. Recently, the treatment strategy for HCC has been strictly defined in Japan [2] on the basis of tumor status, vessel invasion, extrahepatic metastasis and liver function. In this strategy, for solitary tumors or no more than three tumors,

none larger than 3 cm without macroscopic vessel invasion, surgical resection, ablation therapy and transarterial embolization are recommended [2]. On the other hand, there are many criteria for treatment of HCC in the world. Most widely used criteria is classification of Barcelona Clinic Liver Cancer (BCLC) [3]. BCLC classification includes not only tumor status, vessel invasion and extrahepatic metastasis, but also performance status, portal vein pressure and bilirubin level. In very early and early stage (stage 0 and A) of BCLC classification, resection, ablation therapy, ethanol injection or liver transplantation are recommended [4]. In recent years, some studies have reported that surgical resection shows better outcomes compared with other therapies [5, 6]. However,

*Correspondence:

Shinichiro Yamada

yamada.shinichirou@tokushima-u.ac.jp

Department of Digestive and Transplant Surgery, Tokushima University Hospital, 3-18-15 Kuramoto-cho, Tokushima City, Tokushima 770-8503, Japan



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

prognosis of early HCC after surgical resection varies. In some patients, tumors recur and progress very quickly [7]. This may be due to tumor heterogeneity, with some tumors manifesting highly aggressive characteristics [8]. Therefore, modern practices would benefit from pre-operative methods that evaluate tumor characteristics accurately.

Recent advances in diffusion-weighted imaging (DWI) of magnetic resonance imaging (MRI) have radically improved detection and characterization of solid tumors [9]. DWI is a functional MRI technique that can evaluate water molecule diffusion and assess the histopathological condition of tissues and organs, using a high scan speed without a contrast agent. Apparent diffusion coefficient (ADC) values provide a quantitative image of diffusion characteristics [10]. More specifically, ADC values decrease in areas where diffusion is restricted, such as rich stroma or tissues with high cellularity. Recently, ADC values have been shown to predict prognosis in various cancers [11, 12]. We reported that ADC values can predict prognosis of intrahepatic cholangiocarcinoma [13]. ADC values can also be used to estimate histological grade of HCC [14]. Furthermore, some studies have reported that ADC values can predict early recurrence [15] and metastatic recurrence [16] after curative resection of HCC. However, to our knowledge, no studies have reported prognostic prediction of overall survival using ADC values in early HCC; BCLC stage 0 and A.

This study therefore investigated the usefulness of ADC values in prognostic prediction of early HCC; BCLC stage 0 and A.

Methods

Patients and MRI imaging

In this study, we enrolled 112 patients who underwent surgical resection for early HCC of BCLC stage 0 and A at the Department of Surgery, Tokushima University Hospital, between January 2004 and December 2020. We included only patients who (a) had undergone pre-operative abdominal MRI, including DWI, within 4 weeks before surgery; (b) had no history of previous treatment prior to surgery, and were without extrahepatic metastasis; and (c) had pathologically proven HCC. For gallbladder cancer, we defined pathological parameters, morphological parameters, and Japanese Tumor-Node-Metastasis stage, in accordance with the Liver Cancer Study Group of Japan [17].

We obtained MR images using 1.5-T superconducting units (Signa HD/Explorer, GE Medical Systems, Milwaukee, WI, USA) with 8-channel phased-array coil. We recorded fast spin-echo T2-weighted images and DWI ($b=0, 20, 800$ s/mm²). We measured minimum ADC values ($\times 10^{-3}$ mm²/s) associated with tumors

within regions of interest (ROI) using manual tracing from ADC maps on Synapse Vincent (Fujifilm Medical, Tokyo, Japan) [13]. Synapse Vincent can calculate mean, minimum, and maximum values from free-form green outlines automatically (Fig. 1). In this study, we used minimum ADC values because several studies have reported a significant correlation between such values and histological grade in HCC [14, 18]. Patients were divided into two groups: ADC^{High} group ($n=82$) and ADC^{Low} group ($n=34$). The cut-off value of 0.84×10^{-3} mm²/s was defined via ROC analysis (Fig. 2). This study was approved by the ethics committee of Tokushima University Hospital.

Statistical analysis

Continuous variables are presented as min-max (median) and the unpaired Mann–Whitney U test was used. Other factors are presented as number and Fisher's exact test was used for differentiation. We generated overall survival (OS) and disease-free survival (DFS) curves using the Kaplan–Meier method, and compared differences using the log-rank test. Variables with a p value < 0.1 in univariate analyses were included in the multivariate survival analysis by using a Cox proportional-hazards model [19]. For all statistical analyses, $p < 0.05$ was considered significant. All statistical analyses were performed using statistical software (JMP 8.0.1, SAS Campus Drive, Cary, NC, USA).

Results

Clinicopathological features

Table 1 summarizes clinicopathological variables associated with both ADC^{Low} and ADC^{High} groups. Patients in the ADC^{Low} group showed significantly higher protein induced by vitamin K absence-II (PIVKA-II) level ($p=0.02$). However, the two groups did not significantly differ with respect to age, sex, liver function, operation procedure, pathological findings of non-cancerous liver tissue and tumor factors such as tumor size, number, portal invasion, and stage.

Overall and disease-free survival rates

The OS rate of HCC patients after hepatectomy in the ADC^{Low} group was significantly worse than that in the ADC^{High} group ($p < 0.01$; Fig. 3). Three-year OS rates in the ADC^{Low} group and in the ADC^{High} group were 81% and 98%, respectively. Univariate analysis of OS identified high PIVKA-II (≥ 400 mAU/ml), multiple tumors, infiltrative growth pattern, and low ADC values as prognostic OS factors ($p < 0.1$). In multivariate analysis, infiltrative growth pattern and low ADC values were identified as independent prognostic factors ($p < 0.05$; Table 2). DFS rates after hepatectomy (Fig. 4) did not




Fig. 1 Calculation of ADC values using SYNAPSE VINCENT. This application automatically calculates mean, minimum, and maximum values within free-form green outlines (manual tracing)




Fig. 2 ROC analysis to determine appropriate cut-off value for minimum ADC values. Cut-off value was $0.84 \times 10^{-3} \text{mm}^2/\text{s}$ with area under the curve of 0.62

significantly differ between the two groups ($p=0.24$). However, regarding recurrence patterns, the rate of multiple liver and extrahepatic recurrence was significantly higher in the ADC^{Low} group compared with the ADC^{High} group (68.8% versus 35.0%, $p < 0.05$; Fig. 5). Furthermore, early recurrence rates within 2 years after surgery were significantly higher in the ADC^{Low} group

compared with the ADC^{High} group (81.3% versus 27.5%, $p < 0.01$; Fig. 6).

Discussion

In this study, we demonstrate the potential role of ADC values in prognostic prediction for patients with early HCC after surgery: BCLC stage 0 and A. Despite therapeutic improvement, the recurrence rate after treatment for HCC remains high [18]. About half of the patients in this study developed tumor recurrence. Preoperative methods that predict prognosis in patients with early HCC are essential for establishing an appropriate therapeutic strategy, and help determine more aggressive treatments for high-risk patients to decrease post-operative recurrence.

In this study, low ADC values correlated with higher PIVKA-II levels and higher rates of infiltrative growth pattern. PIVKA-II is now established as a powerful prognostic factor for HCC [20, 21]. Infiltrative growth pattern was found to be associated with worse prognosis related to hypoxic/fibrotic tumor microenvironment or high expression of stemness-related markers [22].

Regarding the mechanism of variation of ADC values, progression of HCC is associated with increased cellular atypia in viable tumor, such as abnormal mitotic activity and nucleus/cytoplasm ratio [23]. These factors

Table 1 Patient characteristics in the low ADC group and in the high ADC group

Variable	ADC low (n = 34)	ADC high (n = 82)	P-value
Age (years)	38–84 (70)	38–90 (69)	0.96
Sex (M/F)	25/9	60/22	0.97
Albumin (mg/dl)	3.0–4.8 (3.9)	2.5–4.8 (4.0)	0.12
Platelet ($\times 10^4$ / μ l)	5.5–130 (16.3)	4.6–39.8 (18.4)	0.44
ICG clearance test (%)	2.8–31.3 (10.1)	2.2–53 (9.1)	0.44
Child-Pugh classification (A/B)	34/0	81/1	0.40
Hepatitis (B/ C/non B non C)	8/10/16	18/30/34	0.75
AFP ($< 100 \geq 100$ ng/ml)	30/4	70/12	0.68
PIVKA-II ($< 400 \geq 400$ mAU/ml)	22/12	70/12	0.02
Maximum diameter (cm)	1–12 (3)	0.9–10 (3)	0.96
Tumor number (single/multiple)	28/6	71/11	0.56
Growth type (Eg/Ig)	26/8	71/11	0.19
Portal invasion (–/+)	32/2	81/1	0.18
Stage (I/II/III)	4/25/5	14/60/8	0.62
Type of hepatectomy (minor/major)	29/5	67/15	0.64
Pathological finding (NL/CH/LC)	4/17/13	14/52/16	0.11

ICG indocyanine green, AFP alpha-fetoprotein, PIVKA-II protein induced by vitamin-K absence II, Eg expansive growth, Ig infiltrative growth

NL normal liver, CH chronic hepatitis, LC liver cirrhosis

Continuous variables are presented as min–max (median) and the unpaired Mann–Whitney U test was used. Other factors are presented as number. Fisher’s exact test was used for Differentiation




Fig. 3 Overall survival rate of ADC^{Low} and ADC^{High} groups. The ADC^{Low} group showed significantly worse prognosis than the ADC^{High} group ($p < 0.01$)

could theoretically reduce free diffusion of water molecules within the intracellular space, and lead to reduced ADC values [24]. However, microscopic or macroscopic tumor necrosis results in increased ADC values [25]. These tumor characteristics could influence ADC values associated with HCC. Lee et al. [15] report that low ADC values were associated with early recurrence of HCC after surgery. Mori et al. [16] showed that low ADC values correlate with poorly differentiated tumor, micro vessel invasion, and metastatic recurrence. However, no studies have reported prognostic prediction of overall

survival using ADC for early HCC of BCLC stage 0 and A after surgery. Our study also demonstrated that low ADC values are associated with progressive tumor status. Although DFS showed no significant difference between ADC^{High} and ADC^{Low} groups, patterns of early and aggressive recurrence characterized the ADC^{Low} group, which might indicate poor prognosis in overall survival.

Preoperative non-invasive prediction of aggressive HCC characteristics based on imaging technology is very important for decreasing recurrence after surgical resection. Low ADC values may help surgeons select appropriate surgical procedures, such as wide resection margin, or liver transplantation. Furthermore, HCC patients with low ADC values should be followed up intensively after surgery [15]. Regarding other methods for prognostic prediction, Li et al. [26] reported that fluorodeoxyglucose (FDG) positron emission tomography (PET) and computed tomography (CT) could estimate microvascular invasion and DFS. However, PET/CT is not common for preoperative assessment of HCC. MRI is more commonly used for preoperative assessment, and has the advantage of combining tumor detection, prediction of liver function, and preoperative simulation [27].

The present study has several limitations. First, selection bias might exist because we retrospectively analyzed only patients with HCC who underwent MRI. Second, patients in our study were enrolled in only one center, and the number of cases was relatively small. Thus,

Table 2 Multivariate analysis for overall survival

Variable	Three-year survival rate (%)	Univariate p-value	Multivariate HR (95% C.I.)	p-value
Age (< 70/≥70 years)	95.8/91.6	0.83		
Sex (M/F)	95.9/88.2	0.80		
AFP (< 100/≥ 100 ng/ml)	94.1/92.3	0.29		
PIVKA-II (< 400/≥400 mAU/ml)	96.2/83.7	0.04	1.94 (0.69–5.43)	0.21
Tumor diameter (< 3/≥ 3 cm)	92.4/94.8	0.24		
Tumor number (single/multiple)	96.5/85.9	0.09	1.91 (0.67–5.45)	0.22
Growth type (Eg/Ig)	96.1/80.9	< 0.01	3.64 (1.42–9.30)	< 0.01
Portal invasion (–/+)	93.6/100	0.52		
ADC (high/low)	98.4/81.8	< 0.01	3.49 (1.39–8.79)	< 0.01




Fig. 4 Disease-free survival rate of ADC^{Low} and ADC^{High} groups. There was no significant difference between the two groups




Fig. 6 Rate of early recurrence within 2 years of surgery. The ADC^{Low} group showed higher rates of early recurrence compared with the ADC^{High} group (p < 0.01)




Fig. 5 Recurrent patterns of ADC^{Low} and ADC^{High} groups. The ADC^{Low} group showed significantly higher rates of multiple liver and extra-hepatic recurrence (p < 0.05)

further research with a larger, prospectively collected population is warranted to confirm these results.

Conclusion

ADC values from DWI-MRI might be useful for prognostic prediction of patients with early HCC: BCLC stage 0 and A.

Abbreviations

- BCLC Barcelona clinic liver cancer
- ADC Apparent diffusion coefficients
- DWI Diffusion-weighted images
- MRI Magnetic resonance imaging
- HCC Hepatocellular carcinoma
- PIVKA-II Protein induced by vitamin K absence-II
- OS Overall survival
- DFS Disease-free survival
- AFP Alpha-fetoprotein
- PIVKA-II Protein induced by vitamin-K absence II
- Eg Expansive growth
- Ig Infiltrative growth
- HR Hazard ratio

Acknowledgements

We thank Edanz (<https://jp.edanz.com>) for editing the English text of a draft of this manuscript.

Author contribution

SY, YM and MS designed the study, SY, TI, YS, HT, YW, CN contributed to data collection. SY and CN participated in writing the manuscript. All authors read and approved the final manuscript.

Funding

This study was partly supported by TAIHO PHARMACEUTICAL CO., LTD. Japan.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

In this study, all methods were carried out in accordance with relevant guidelines and regulations. This study was approved by the ethics committee of Tokushima University Hospital (Tokushima, Japan; no. 4251). The requirement for informed consent was waived with approval by the ethics committee of Tokushima University Hospital, and an information disclosure statement was uploaded onto the homepage of our hospital website for opt-out.

Consent for publication

Not applicable.

Competing interests

M.S. received research grants from TAIHO PHARMACEUTICAL CO., LTD., TSUMURA & CO. Other authors have no competing interest related to this study.

Received: 24 October 2022 Accepted: 20 December 2022

Published online: 11 January 2023

References

- Marrero JA, Welling T. Modern diagnosis and management of hepatocellular carcinoma. *Clin Liver Dis.* 2009;13:233–47.
- Clinical practice guidelines for hepatocellular carcinoma. The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.
- Ince V, Sahin TT, Akbulut S, Yilmaz S. Liver transplantation for hepatocellular carcinoma: historical evolution of transplantation criteria. *World J Clin Cases.* 2022;10:10413–27.
- European Association For The Study Of The Liver 1; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol.* 2012;56:908–43.
- Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection Versus local ablation therapies for Hepatocellular Carcinoma within the Milan Criteria: a systematic review and Meta-analysis. *Ann Surg.* 2021;273:656–66.
- Oh JH, Sinn DH, Choi GS, Kim JM, Joh JW, Kang TW, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. *Ann Surg Treat Res.* 2020;99:238–46.
- Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. *Gut.* 2014;63:844–55.
- Lin DC, Mayakonda A, Dinh HQ, Huang P, Lin L, Liu X, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. *Cancer Res.* 2017;77:2255–65.
- Parikh T, Drew SJ, Lee VS, Wong S, Hecht EM, Babb JS, Taouli B. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. *Radiology.* 2008;246:812–22.
- Jiang T, Xu JH, Zou Y, Chen R, Peng LR, Zhou ZD, et al. Diffusion-weighted imaging (DWI) of hepatocellular carcinomas: a retrospective analysis of the correlation between qualitative and quantitative DWI and tumour grade. *Clin Radiol.* 2017;72:465–72.
- Kurosawa J, Tawada K, Mikata R, Ishihara T, Tsuyuguchi T, Saito M, Shimofusa R, Yoshitomi H, Ohtsuka M, Miyazaki M, Yokosuka O. Prognostic relevance of Apparent Diffusion Coefficient obtained by diffusion-weighted MRI in pancreatic Cancer. *J Magn Reson Imaging.* 2015;42:1532–7.
- Parsian S, Giannakopoulos NV, Rahbar H, Rendi MH, Chai X, Partridge SC. Diffusion-weighted imaging reflects variable cellularity and stromal density present in breast fibroadenomas. *Clin Imaging.* 2016;40:1047–54.
- Yamada S, Morine Y, Imura S, Ikemoto T, Arakawa Y, Saito Y, Yoshikawa M, Miyazaki K, Shimada M. Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma. *J Hepatobiliary Pancreat Sci.* 2020;27:388–95.
- Nishie A, Tajima T, Asayama Y, Ishigami K, Kakiyama D, Nakayama T, Takayama Y, et al. Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma. *Eur J Radiol.* 2011;80:e29–33.
- Lee S, Kim SH, Hwang JA, Lee JE, Ha SY. Pre-operative ADC predicts early recurrence of HCC after curative resection. *Eur Radiol.* 2019;29:1003–12.
- Mori Y, Tamai H, Shingaki N, Hayami S, Ueno M, Maeda Y, Moribata K, Deguchi H, et al. Hypointense hepatocellular carcinomas on apparent diffusion coefficient mapping: pathological features and metastatic recurrence after hepatectomy. *Hepatol Res.* 2016;46:634–41.
- Liver Cancer Study group of Japan. Clinical findings. In: Makuuchi M, editor. The general rules for the clinical and pathological study of primary liver cancer. 2nd English edition. Tokyo: Kanehara Co; 2003. pp. 6–28.
- Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: steps forward but still a long way to go. *World J Hepatol.* 2015;7:566–74 1302–9.
- Akbulut S, Sahin TT, Yilmaz S. Comment on pediatric living donor liver transplantation decade progress in Shanghai: characteristics and risks factors of mortality. *World J Gastroenterol.* 2020;26:4564–6.
- Pote N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. *J Hepatol.* 2015;62:848–54.
- Park H, Kim SU, Park JY, Kim DY, Ahn SH, Chon CY, Han KH, Seong J. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. *Liver Int.* 2014;34:313–21.
- Rhee H, Chung T, Yoo JE, Nahm JH, Woo HY, Choi GH, Han DH, Park YN. Gross type of hepatocellular carcinoma reflects the tumor hypoxia, fibrosis, and stemness-related marker expression. *Hepatol Int.* 2020;14:239–48.
- Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. *Cancer.* 1954;7:462–503.
- Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. *Neoplasia.* 2009;11:102–25.
- Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. *Radiology.* 2005;237:492–9.
- Li Y, Zhang Y, Fang Q, Zhang X, Hou P, Wu H, Wang X. Radiomics analysis of [18F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma. *Eur J Nucl Med Mol Imaging.* 2021;48:2599–614.
- Yamada S, Shimada M, Morine Y, Imura S, Ikemoto T, Saito Y, Takasu C, Yoshikawa M, Teraoku H, Yoshimoto T. A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging. *PLoS ONE.* 2019;14: e0210579.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.